Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Orally active thrombin inhibitors prepared at ADIR as anticoagulants

Oct. 19, 1998

Heterocyclic anticoagulants in development at BioChem Pharma

Oct. 15, 1998

Low-dose xemilofiban + high-dose ASA provides protection in canine arterial thrombosis model

Oct. 9, 1998

Sibrafiban interactions studied in canine model

Oct. 9, 1998

Rovi introduces LMW heparin in Spain

Oct. 7, 1998

Candidate gene therapy for hemophilia gives promising results in canine studies

Oct. 5, 1998

Potent, long-acting TxA2 receptor antagonist enters Pfizer development pipeline

Oct. 1, 1998

YM-377 as a treatment for coronary occlusive diseases

Sep. 29, 1998

U.S. patent issues for Bio-Technology General's anticoagulant polypeptide

Sep. 28, 1998

Organon designs nonpeptide thrombin inhibitors mimicking D-Phe-Pro-Arg

Sep. 25, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...